Hims & Hers Reports Mixed Q4 Results as Earnings Beat Offsets Revenue Miss

Key Facts

1Hims & Hers issued a weak financial outlook for the upcoming period.

2The company is a telehealth provider known for its compounded weight-loss drugs.

Hims & Hers Health Inc. (HIMS) reported mixed fourth-quarter financial results, with revenue reaching $617.82 million, narrowly missing analyst estimates of $619.22 million. Despite the revenue miss, the company delivered a significant beat on earnings per share (EPS), reporting $0.08 compared to the projected $0.03. Operational growth remained a highlight as the telehealth provider's subscriber base officially surpassed the 2.5 million mark. These figures provide a more nuanced picture following recent investor concerns regarding the company's forward-looking financial guidance. While the subscriber milestone indicates sustained demand, the slight revenue shortfall underscores the competitive pressures in the digital healthcare landscape. Investors are now weighing the strong profitability beat against the company's long-term growth trajectory in the compounded weight-loss medication sector.

8 months ago

Version History

Version 18 months ago

What changed: The story was updated to include actual Q4 figures, revealing an EPS beat against a slight revenue miss, alongside reaching a new subscriber milestone.